Details of the Drug
General Information of Drug (ID: DM2LA9X)
Drug Name |
[3H]p-MPPF
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
155204-26-5; p-MPPF; MPPF; CHEMBL286607; UNII-81KHI46E5L; 81KHI46E5L; 4-fluoro-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylbenzamide; 4-Fluoro-N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridinyl)benzamide; 4-Fluoro-N-{2-[4-(2-methoxy-phenyl)-piperazin-1-yl]-ethyl}-N-pyridin-2-yl-benzamide; [3H]p-MPPF; MPPF authentic; Lopac-M-226; GTPL81; AC1O7G4Q; Lopac0_000825; SCHEMBL4014204; CTK4C8576; DTXSID20424966; ZINC52542163; BDBM50035513; AKOS022184256; CCG-204909; FC-1062; NCGC00162265-01; NCGC00015641-03
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 434.5 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.9 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 7 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 6 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References